Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
OB-HTN
Sympathetic Neural Patterns and Transduction in Obesity-associated Hypertension
1 other identifier
interventional
100
1 country
1
Brief Summary
The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1 hypertension
Started Jul 2021
Longer than P75 for early_phase_1 hypertension
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 6, 2021
CompletedFirst Posted
Study publicly available on registry
April 9, 2021
CompletedStudy Start
First participant enrolled
July 18, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
August 24, 2025
August 1, 2025
5.1 years
April 6, 2021
August 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Blood flow measured by doppler ultrasound
brachial and femoral artery blood flow
Acutely on the day of study
Muscle sympathetic nervous system activity
recording of sympathetic nervous system activity from the peroneal or radial nerve
Acutely on the day of study
Study Arms (4)
Healthy Control
EXPERIMENTALHealthy age matched controls with no history of cardiovascular disease and normal bodyweight
Hypertensive
EXPERIMENTALHypertensive adults who are not obese
Obese
EXPERIMENTALObese adults who are not hypertensive
Obese-hypertensive
EXPERIMENTALObese adults who are being treated for hypertension
Interventions
intra-arterial infusion of neuropeptide Y
Eligibility Criteria
You may qualify if:
- Control - BMI\<30, age 18-55
- Hypertensive - BMI\<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI\>30, age 18-55 Obese-hypertensive- BMI\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring
You may not qualify if:
- All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas Southwestern Medical Center
Dallas, Texas, 75231, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Instructor
Study Record Dates
First Submitted
April 6, 2021
First Posted
April 9, 2021
Study Start
July 18, 2021
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
August 24, 2025
Record last verified: 2025-08